Bayer, the German pharmaceutical and agrochemical company, announced plans to invest $2.2 billion in a new production facility in New Albany, Ohio. This site will combine the manufacture of pharmaceutical active ingredients and finished medicines, creating around 600 skilled jobs.
Bayer’s CEO, Bill Anderson, emphasized the importance of the U.S. as a manufacturing and innovation hub, stating that the new facility will enhance their capacity to deliver high-quality medicines to patients domestically and internationally. Over the past five years, Bayer has invested more than $7 billion in U.S. pharmaceutical research, development, and production.
